Dumping causes key Indian bulk drug prices to plunge

12 November 1999

Tough competition and dumping by China have forced some Indianpharmaceutical companies to sell their bulk drugs at well below cost and government-controlled prices, the Financial Express reported. Quoting industry sources, it said that drugs selling at huge discounts include the antimalarial chloroquine, the tuberculosis drug rifampicin and the antiulcerant famotidine.

Chloroquine is being sold at around 850-900 rupees ($10-$20) per kilo, a discount of over 36% compared with the official notified price of 1,340 rupees per kilo. Rifampicin is currently priced at around 4,100-4,200 rupees per kilo, against the official price of 4,885 rupees a kilo.

Cloxacillin (oral grade), famotidine and vitamin C are currently sold at an average price of 1,550 rupees (official price 2,356 rupees), 2,400 rupees (4,684 rupees) and 430 rupees (526 rupees) a kilo respectively. "We are forced to sell even below costs due to competition and acute dumping pressures," a senior pharmaceutical company official was quoted as saying.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight